Recce Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
10.30
16.70
25.50
53.10
Gross Income
10.30
16.70
25.50
53.10
SG&A Expense
553.50
4,804.70
3,159.10
2,867.40
EBIT
563.80
4,821.30
3,184.60
2,920.50
Unusual Expense
-
190.60
-
-
Non Operating Income/Expense
113.50
3.60
28.40
-
Interest Expense
0.30
9.00
2.40
54.30
Pretax Income
450.20
4,973.30
3,164.80
2,962.80
Income Tax
-
132.90
139.30
1,288.50
Consolidated Net Income
450.20
4,840.40
3,025.50
1,674.30
Net Income
450.20
4,840.40
3,025.50
1,674.30
Net Income After Extraordinaries
450.20
4,840.40
3,025.50
1,674.30
Net Income Available to Common
450.20
4,840.40
3,025.50
1,674.30
EPS (Basic)
0.01
0.09
0.04
0.02
Basic Shares Outstanding
67,441.40
56,224.60
76,612.60
84,724.20
EPS (Diluted)
0.01
0.09
0.04
0.02
Diluted Shares Outstanding
67,441.40
56,224.60
76,612.60
84,724.20
EBITDA
553.50
4,804.70
3,159.10
2,867.40
Non-Operating Interest Income
0.40
44.10
50.60
12

About Recce

View Profile
Address
Gateway Tower
Sydney Western Australia (WA) 2000
Australia
Employees -
Website http://www.recce.com.au
Updated 07/08/2019
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Bentley, Australia.